163 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and at least one F508del alleles: 96-week interim results from an open-label extension study.

Autor: Wainwright, C. (AUTHOR), McColley, S. (AUTHOR), McNally, P. (AUTHOR), Powers, M. (AUTHOR), Ratjen, F. (AUTHOR), Rayment, J. (AUTHOR), Retsch-Bogart, G. (AUTHOR), Roesch, E. (AUTHOR), Ahluwalia, N. (AUTHOR), Chin, A. (AUTHOR), Chu, C. (AUTHOR), Lu, M. (AUTHOR), Menon, P. (AUTHOR), Moskowitz, S. (AUTHOR), Waltz, D. (AUTHOR), Weinstock, T. (AUTHOR), Xuan, F. (AUTHOR), Zelazoski, L. (AUTHOR), Davies, J. (AUTHOR)
Zdroj: Journal of Cystic Fibrosis. 2022 Supplement 2, Vol. 21, pS96-S96. 1p.
Databáze: Academic Search Ultimate
Externí odkaz: